STXS Earnings Prediction
The chart below shows how STXS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, STXS sees a +8.40% change in stock price 10 days leading up to the earnings, and a +9.43% change 10 days following the report. On the earnings day itself, the stock moves by -5.39%. This data can give you a slight idea of what to expect for the next quarter's release.
STXS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
6.34M
38.88%
-31.06%
Gross Margin
50.73%
-15.42%
13.82%
Operating Margin
-120.30%
3.54%
74.35%
Net Margin
-118.53%
7.35%
76.10%
EPS
-0.09
-28.57%
12.50%
No Data Available
STXS Earnings Analysis
Stereotaxis Inc Corporation (STXS.A) Earnings Conference Call
Positive
Revenue Increase Announcement: Stereotaxis reported a 39% year-over-year increase in revenue for Q4 2024, totaling $6.3 million compared to $4.6 million in Q4 2023.
System Sales Growth: System revenue for Q4 2024 was $1.4 million, a significant increase from $0.1 million in the prior year, indicating strong growth in system sales.
Recurring Revenue Increase: Recurring revenue for Q4 2024 was $4.9 million, reflecting a full quarter’s contribution from the recent acquisition of APT, compared to $4.5 million in Q4 2023.
Strong System Backlog: The company started 2025 with a system backlog of $15.2 million, indicating strong demand for their products.
CE Mark Approval for MAGIC Catheter: Stereotaxis received CE Mark approval for the MAGIC catheter in Europe, with first sales expected in March, projected to generate approximately $1 million in revenue per quarter by year-end.
CE Mark Approval Milestone: The GenesisX robot received CE Mark approval and is expected to be installed in a European hospital this summer, marking a significant milestone for the company.
Regulatory Submission Announcement: The company announced the regulatory submission of MAGIC Sweep, a robotically navigated high-density mapping catheter, with expected approvals in both Europe and the US in Q3 2025.
Robotic PSA Catheter Progress: Stereotaxis is making progress with partners in robotic PSA catheter solutions, with at least one solution expected to enter first-in-human testing this year.
Regulatory Approval for Catheter: The company submitted EMAGIN, their first vascular catheter, for regulatory approval, which is expected to expand their market reach into neuro interventions and interventional cardiology.
Regulatory Approval in China: Stereotaxis' partner MicroPort received regulatory approval for the Genesis robot and related systems in China, opening up significant market opportunities in that region.
Digital Surgery Platform Development: The company is developing a digital surgery platform, SynX, which will enhance connectivity and AI capabilities in cath labs, with plans to unveil it at an upcoming conference.
Negative
Earnings Miss Report: Stereotaxis, Inc. misses on earnings expectations with reported EPS of $-0.09, below the expected $-0.06.
Increased Operating and Net Loss: Operating loss and net loss in Q4 2024 were $7.6 million and $7.5 million, respectively, compared to $5.3 million and $5 million in the previous year, indicating worsening financial performance.
Increased Operating Loss: Adjusted operating loss for Q4 2024 was $4 million, up from $2.7 million in the previous year, showing increased operational inefficiencies.
Adjusted Operating Loss Comparison: Full year 2024 adjusted operating loss of $12.8 million compared to $11.3 million in the prior year, reflecting ongoing financial struggles.
Free Cash Flow Challenges: Negative free cash flow for the full year was $8.5 million, although it was an improvement from $9.5 million in 2023, indicating ongoing cash management challenges.
Acquisition Impact on Margins: Recurring revenue gross margin was negatively impacted by the acquisition of APT, which caused minimal accounting gross margin on the sale of acquired inventory, affecting profitability.
Low Gross Margin Challenges: System gross margin was only 20%, reflecting the allocation of significant overhead expenses on low production volume, which is unsustainable for long-term growth.
STXS FAQs
How does STXS typically perform around its earnings report dates?
Is Stereotaxis Inc (STXS) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
STXS Earning Call Sentiment
Stereotaxis, Inc. (AMEX:STXS) Q4 2024 Earnings Call Transcript
STXS.A
3.31%Positive
Despite a 39% increase in Q4 revenue, operating losses have widened, and there are significant supply chain challenges. The absence of a share repurchase program and conservative guidance further dampen sentiment. While there are promising product developments, regulatory and market uncertainties, especially in China, pose risks. The Q&A session highlighted management's inability to provide clear timelines for key product approvals, adding to investor concerns. Overall, the negative financial indicators and uncertainties outweigh the positive revenue growth.
